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INTRODUCTION
Hemostasis is a key component of vascular homeostasis that prevents blood loss following vessel injury, whereas also maintaining vascular patency. It is achieved, in part, through a cascade of serine proteases that are sequentially activated from precursors called zymogens, culminating in formation of the effector protease, thrombin, and ultimately in the formation of a blood clot [1] . Normally, this process is tightly regulated, however, a failure of the system to respond appropriately because of a host of factors can lead to bleeding or thrombotic complications. Currently, there are highly effective strategies for the treatment and prevention of thrombosis [2] , but hemostatic management of patients with excessive bleeding remains a major challenge. Bleeding can occur in a variety of clinical scenarios, including trauma, surgery, anticoagulation, and coagulation factor deficiencies such as hemophilia. In some situations, where bleeding is occurring from a single, accessible source, direct endoscopic, surgical, or vascular approaches can be very effective at arresting bleeding [3] [4] [5] [6] . However, when bleeding occurs more diffusely, when the bleeding source is difficult to access, or when traditional treatments for inherited bleeding disorders fail, alternative therapies may be more appropriate. In this review, we summarize a new technology, zymogen-like factor Xa, that has the potential to serve as a rapid and versatile hemostatic agent for the treatment of bleeding conditions. We will discuss the preclinical
PROHEMOSTATIC MOLECULES-OVERVIEW
There is a great deal of interest in the development of protein therapeutics to mitigate bleeding in certain clinical settings. Over the past two to three decades, largely as a result of work aimed at preventing or stopping hemophilia-associated bleeding, several prohemostatic agents have been developed. Examples include prothrombin complex concentrates [PCCs or activated PCCs (aPCCs)] and recombinant factor VIIa (rFVIIa), which are used to improve hemostasis and control bleeding [7] [8] [9] .
PCCs are a heterogeneous group of plasma-derived products that were originally developed to treat severe factor IX deficiency (hemophilia B) before purified factor IX was available [10] . It is now typically used for warfarin reversal, especially in patients who may not be able to tolerate large volumes of fresh frozen plasma, and is also used to treat patients with rare vitamin K-dependent factor deficiencies. There are three-factor and four-factor forms, with both containing factor IX, factor X, and prothrombin, but with 4-factor PCCs also containing factor VII [10] . Most preparations also contain the anticoagulant proteins C and S [11] . rFVIIa is a widely used bypassing agent for hemophilia A and hemophilia B patients with inhibitors to enhance factor Xa generation through the extrinsic pathway [9, 12] . aPCCs are a plasma-derived product used, like rFVIIa, to treat bleeding in hemophilia patients with inhibitors [12, 13] . Despite their name, aPCCs only contain a significant concentration of one activated factor, factor VIIa [14] . The other components are zymogens factor IX, factor X, and prothrombin, with very little factor IXa, factor Xa, or thrombin present. The mechanism of action of aPCCs has not been fully elucidated, although some studies have suggested that the prothrombin present in the product is critical to its function [15] [16] [17] .
A common feature of these direct prohemostatic approaches for hemophilia is that they work by accelerating the formation of factor Xa. The outcome of these strategies is to boost thrombin generation to provide adequate hemostasis. In principle, a more straightforward approach is direct infusion of factor Xa. Factor Xa is strategically positioned as the ideal enzyme to bypass defective clotting in hemophilia and potentially other clinical scenarios. However, early attempts to document the usefulness of factor Xa were disappointing largely because of its very short half-life (<1 min) caused by rapid inactivation by endogenous plasma inhibitors, such as antithrombin (AT) and tissue factor pathway inhibitor (TFPI) [18] .
ZYMOGEN-LIKE FACTOR XA-BIOCHEMICAL PERSPECTIVES
The problems associated with wild-type factor Xa essentially eliminate the possibility that it could be an effective prohemostatic agent. To address these issues, we bioengineered a factor Xa that could overcome protective inhibitory mechanisms without compromising hemostatic benefit. Specifically, proteolytic activation of factor Xa from its precursor factor X at a highly conserved site (e.g., R 15 [20] [21] [22] . This leads to a series of conformational changes that yield the mature protease, factor Xa. The relative abundance of these conformations and their equilibrium distribution is determined, in part, by the degree to which the new amino terminus is stabilized within the hydrophobic pocket [23] . To alter this process and the equilibrium of conformations that normally exist, we changed the amino acid at position 16 or 17 to make the ensuing structural change suboptimal and create a 'zymogen-like state.' Biochemical characterization of a range of zymogen-like variants revealed they have varying degrees of catalytic impairment (5 to 1000-fold; see Table 1 ) [24] . They also have partial resistance to circulating inhibitors (e.g., AT and TFPI) and, consequently a prolonged half-life in plasma. Interestingly, variants with lowest catalytic activity (the most zymogen-like) were the most resistant to inhibitors [24,25 & ]. Importantly, as the zymogen-like state has plasticity and is highly dynamic, ligands that engage the enzyme can readily alter its conformational equilibrium. An important biological consequence of this is the activity of zymogen-like factor Xa can be thermodynamically
KEY POINTS
New therapeutic approaches are needed to control excessive bleeding.
Engineering coagulation factor Xa has allowed for development of 'zymogen-like' factor Xa variants that are biologically active only at the site where coagulation is needed and can overcome the inherent regulatory mechanisms of coagulation.
Preclinical development of zymogen-like factor Xa shows that it is efficacious in numerous bleeding scenarios, and in early clinical testing, it appears safe and well tolerated.
rescued by binding factor Va, resulting in a prothrombinase enzyme with near-normal procoagulant activity (Table 1) 
ZYMOGEN-LIKE FACTOR XA FOR USE IN HEMOPHILIA
Hemophilia is an inherited, X-linked bleeding disorder caused by deficiency of factor VIII or factor IX. Replacement of the deficient factor with recombinant or plasma-derived protein is the standard of care. In total, 5-30% of patients develop neutralizing autoantibodies to factor VIII or factor IX, necessitating use of prohemostatic bypass agents such as rFVIIa or aPCCs [27] . These agents can achieve hemostasis in most patients with inhibitors, but are not always effective and do not completely normalize thrombin generation [9, 28, 29] . There is also an inherent prothrombotic risk associated with bypass therapies. Finally, aPCCs are plasma derived, which increases the risk of blood-borne disease [9, [30] [31] [32] .
We hypothesized that zymogen-like factor Xa might be an effective alternative to existing bypassing agents because of its unique properties and position in the coagulation cascade. In-vitro and ex-vivo studies of increasing complexity showed that factor Xa I16L , a prototypical zymogen-like factor Xa species, was highly effective in promoting thrombin generation in hemophilic plasma with or without inhibitors and in hemophilic blood [25
As expected from previous biochemical studies, these effects were factor Va dependent. Initial preclinical studies in hemophilic mice indicate that factor Xa I16L appears well tolerated and effective after a single dose when administered either before or after injury in multiple models [34] . Importantly, repeated infusions at the effective dose of factor Xa I16L did not result in systemic activation of coagulation, with no significant changes in levels of fibrinogen, platelets, thrombin-AT or D-dimer over an extended time course in either hemophilic or wild-type mice. Further, histopathological evaluation in different tissues revealed no evidence of treatment-related increases in fibrin deposition [34] .
Despite its zymogen-like character, factor Xa ,26]. However, it may be ideal for acute bleeding, where the desired effect is to stop blood loss quickly without prolonged activation of coagulation. As ]. Together these studies underscore that the tunability of the factor X/factor Xa zymogen-to-protease transition allows for the development of therapeutics with broad applicability, and prompted us to explore other clinical applications outside of hemophilia.
ZYMOGEN-LIKE FACTOR XA CAN OVERCOME DIRECT ORAL ANTICOAGULANTS
In 2010, dabigatran (Ridgefield, CT), the first orally bioavailable direct thrombin inhibitor, was approved as an anticoagulant for several indications including primary prevention of stroke in patients with nonvalvular atrial fibrillation, and prevention and treatment of venous thromboembolism [35, 36] . Since then, several orally administered direct factor Xa inhibitors, including rivaroxaban, apixaban, and edoxaban, were approved for similar indications [37] [38] [39] [40] [41] [42] [43] [44] [45] . Collectively, the direct thrombin and direct factor Xa inhibitors are known as direct oral anticoagulants (DOACs), and are all active site inhibitors of their respective proteases [46, 47] . Following their introduction, DOACs have gained a tremendous share of an anticoagulant market that was once dominated by the vitamin K antagonist warfarin. By the end of 2014, office visits for the DOACs had nearly surpassed office visits for warfarin [48] . Their rapid adoption is because of several successful phase III clinical trials in thousands of patients showing efficacy equal to warfarin but a significantly reduced risk of bleeding [2, 49] . Further, they have improved pharmacokinetics compared to warfarin which allowed for simpler dosing schemes and decreased or eliminated the need for anticoagulant monitoring [50] . However, like all anticoagulants, DOACs do carry a risk of bleeding [51] . The effects of older anticoagulants like warfarin and heparin can be reversed pharmacologically in the event of bleeding or in the event that patients require urgent or emergent surgery [52] . In contrast, when they were developed, DOACs lacked a reversal agent, which has caused concern [50] . PCCs, aPCCs, or rFVIIa have been shown to have limited to no efficacy as reversal agents for DOACs. In 2015, the food and drug administration (FDA) approved idarucizumab, a monoclonal antibody fragment that binds and neutralizes dabigatran, and can reverse its anticoagulant effects [53 & ]. To date, there are no FDA approved reversal agents for direct factor Xa inhibitors. The most promising reversal approach in development is andexanet (Gla-domainless factor Xa S195A ), a recombinant factor Xa molecule that lacks catalytic activity as well as the ability to bind membranes, making it a scavenger for all direct factor Xa inhibitors [54] .
Neither idarucizumab nor andexanet have catalytic activity, meaning they function as drug-sequestering antidotes. We explored the hypothesis that zymogen-like factor Xa could mitigate the effects of DOACs. We found factor Xa I16L to be highly effective at reversing the effects of anticoagulation in mice treated with rivaroxaban [55 & ]. This was true in multiple injury models. Factor Xa I16L was also between 50 and 300 times more potent than Gladomainless factor Xa S195A , an andexanet biosimilar, supporting the idea that the mechanism by which Factor Xa I16L reverses the effects of rivaroxaban is related to its intrinsic catalytic activity. Factor Xa I16L was also able to reverse the effects of dabigatran in a mouse tail bleeding model [55 & ]. Together, these data suggest that factor Xa I16L may fill an unmet clinical need for a universal rapid countermeasure to the effects of DOACs.
ZYMOGEN-LIKE FACTOR XA FOR ACUTE WARFARIN REVERSAL
As mentioned previously, warfarin can be reversed if needed by replacing the affected clotting factors. Typically, this is achieved with fresh frozen plasma or PCCs. In addition, vitamin K can be administered if reversal is less urgent. However, none of these agents are prohemostatic [52] . Moreover, as these agents either replenish vitamin K or the affected factors, patients who require temporary reversal of anticoagulation (i.e., for invasive procedures) must wait 2-4 days after resumption of warfarin to become therapeutically anticoagulated. As zymogen-like factor Xa has a relatively short half-life, we investigated whether it might be effective as a quick-acting temporary prohemostatic reversal agent for warfarin. Conceptually, this idea is bolstered by recent biochemical work that suggests that prothrombin carboxylation (which is impaired by warfarin treatment) is not crucial for prothrombin activation by prothrombinase [56] . Administering factor Xa I16L to warfarintreated mice in a large-vessel thrombosis model restored clot formation, indicating that, in vivo, factor Xa I16L is able to overcome the effects of warfarin [57] .
CLINICAL DEVELOPMENT OF ZYMOGEN-LIKE FACTOR XA
Given the promising in-vivo animal studies establishing factor Xa I16L as a rapid prohemostatic, its clinical development is underway as PF-05230907. In preclinical pharmacokinetic studies in cynomolgus monkeys, its half-life was found to be $3 min. A dose-dependent decrease in the activated partial thromboplastin time and increase in thrombin-AT levels was also observed, consistent with factor Xa I16L functioning as a prohemostatic 
FUTURE CLINICAL ASSESSMENT: INTRACEREBRAL HEMORRHAGE
Perhaps the most exciting potential application of zymogen-like factor Xa is in the setting of intracerebral hemorrhage (ICH). Spontaneous ICH (bleeding in the brain) is a major cause of death and disability accounting for approximately 8-25% of strokes worldwide [61] [62] [63] . ICH continues to be associated with poor clinical outcomes. Approximately 40% of patients die within 1 month, 1-year mortality is over 50% [64] , and a large number of individuals fail to regain functional independence by 6 months [65] . The current management of ICH is largely supportive and the lack of effective treatment for ICH remains a critical and unmet need [3] . Unfortunately, recent trials exploring mechanism-driven interventions, including surgical hematoma evacuation and intensive blood pressure lowering, have failed to show a clinical benefit [66 & ,67-69] . For these reasons, there has not been an improvement in ICH mortality rate for decades [70] .
Many factors predict ICH outcomes, including age, Glasgow Coma Scale, location of the hemorrhage, and hematoma volume [71] . In particular, hematoma volume has emerged as a therapeutic target because it is a strong predictor of mortality and disability. Furthermore, nearly 40% of ICH patients experience a 33% or greater increase in hematoma volume, and every 10% increase in hematoma volume results in a 5% increased risk of death [72] . Soon after approval of rFVIIa for hemophilia, there was a great deal of interest in exploiting its prohemostatic potential to prevent ICH hematoma volume expansion. A phase II study of rFVIIa for ICH (399 patients randomized) demonstrated a more than 50% decrease in hematoma growth and an absolute mortality decrease of 11% in the 80-mg/kg group [73] . Unfortunately, in a subsequent phase 3 trial [factor seven for acute hemorrhagic stroke (FAST)] of 841 patients, despite a significant decrease in hematoma growth in patients receiving rFVIIa, there was no significant mortality benefit [74] . The results of this trial effectively ended consideration of rFVIIa as a therapeutic agent for ICH. Nonetheless, analysis of the data from the FAST trial has given insight into why rFVIIa decreased hematoma growth without improving outcomes. In particular, one of the major challenges of the FAST trial was the mismatched rate of intraventricular hemorrhage between the high-dose 80-mg/kg rFVIIa group (41%) and the placebo group (29%). Post hoc analysis of the data indicates that, for a subset of patients, particularly younger patients with low levels of intraventricular hemorrhage who receive treatment rapidly may benefit from rFVIIa [75] . These considerations likely translate to any prohemostatic approach that targets hematoma expansion.
Zymogen-like factor Xa, therefore, may have the potential to improve outcomes in certain patients with ICH. As factor Xa is a more downstream activator of coagulation than factor VIIa, zymogen-like factor Xa may be even more effective than rFVIIa at arresting hematoma growth. In addition, as described above, zymogen-like factor Xa but not rFVIIa can overcome the effects of both DOACs and warfarin [55 & ,57] . As anticoagulation is an important cause of ICH [76] , a prohemostatic that can treat ICH regardless of anticoagulation status is desirable. In preclinical models of ICH in rats and mice, factor Xa I16L dose dependently reduced final hematoma volume by as much as 47% [77 & ]. Armed with the lessons learned from the FAST trial, factor Xa I16L (PF-05230907) is currently being studied as a therapeutic for ICH. A phase 1b trial of approximately 50 patients with ICH is currently underway (NCT02687191). Although this is primarily a safety and tolerability study, secondary endpoints will include hematoma growth and neurologic function.
CONCLUSION
Excessive bleeding derived from a range of clinical conditions continues to present a management challenge. Although physical control of the bleeding source is always ideal, in many cases this cannot be achieved; and therefore, there is a need for new therapeutic approaches including prohemostatics. Owing to the mechanism of action of prohemostatics, there is always a risk of thrombotic complications with their use. However, through bioengineering, molecules that minimize this risk can be developed. Early preclinical work with zymogen-like factor Xa demonstrated its ability to enhance clot formation and thereby control bleeding in a localized manner. These studies illustrated that such factor Xa variants can serve as versatile, rapid, pan-hemostatic agents for a variety of bleeding conditions. Ongoing clinical trials will shed more light on the efficacy and safety of this new approach.
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